Physiomics Plc · LSE:PYC
Physiomics — BIO-Europe 2008
11 slides from Physiomics's conference presentation, Nov 19, 2008
Slide 1: Systems Biology for Cancer Drug Development
Systems Biology for Cancer Drug Development Dr. Christophe Chassagnole, COO Copyright Physiomics plc 2008 1
Slide 2: Disclaimer
Disclaimer With the exception of historical information, certain matters discussed in this presentation are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or i
Slide 3: Introduction to Physiomics plc
Introduction to Physiomics plc • Business • Founded 2001, Oxford (UK) based, listed on the LSE (AIM) 2004 • We use computer modelling to understand and predict optimal cancer therapy. • We accelerate the discovery process and reduce development risk. • Focus • Cancer (one of only a handful of compan
Slide 4: Systems Modelling (Computer Simulation)
Systems Modelling (Computer Simulation) • “Systems biology seeks to understand complex biological systems in their entirety by integrating all levels of functional information into a cohesive model”1 • As drug discovery is moving towards the rational design of drugs based on a mechanistic understand
Slide 5: Physiomics' Current Pharmacodynamic Models Portfolio
Physiomics’ Current Pharmacodynamic Models Portfolio Search & Capture Circadian clock (TEMPO) Mitotic poisons (e.g. taxanes) Spindle Checkpoint Growth factor Aurora kinase inhibitors MAPKinase pathway inhibitors CDK inhibitors Chemotherapy Radiotherapy Cell Cycle CDK IAP p53 family inhibitors inhibi
Slide 6: Physiomics' Unique Sales Proposition
Physiomics’ Unique Sales Proposition • Cancer focused (one of only a handful of companies). • Detailed models of cellular biochemistry and drug pharmacology based on prior knowledge to support rational decision making. • Market-driven development of technology to address specific key issues: • Targe
Slide 7: History of Physiomics
History of Physiomics 2001: VC Funding; Scientific Direction from Formation Purchased and developed cell population Prof. David Fell (Oxford Brookes Uni.) software, “SystemCell®”. 2002: First collaboration with Cyclacel Constructed initial cell cycle model. Pharmaceuticals ltd. from networking. Inte
Slide 8: Current Management Team
Current Management Team • Chairman: Dr Paul Harper Dr Paul Harper has over 30 years' experience in the life sciences industry covering both drug development and medical devices. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and Provensis Limited. He has also served as
Slide 9: Business Model
Business Model • Fee-for-service (perform modelling on demand): • Developed proof-of-concept and testimonials from previous & current collaborations (Cyclacel, ValiRx, Eli Lilly) “Physiomics’ service and technology is absolutely superb, we have just had some work carried out and it has saved us very
Slide 10: Summary
Summary • Computer models of cell proliferation and cell death (cancer). • Technology developed for many anti-cancer drug targets. • Developed over many years (since 2001), specifically driven by the market (specialised proprietary cell population simulations, “SystemCell®” and “Virtual Tumour”). •
Slide 11: Thank You
Thank You cchassagnole@physiomics-plc.com www.physiomics-plc.com Copyright Physiomics plc 2008 11